VivoSeq
Neurology

Idiopathic Inflammatory Myopathy

14

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Idiopathic Inflammatory Myopathy is an emerging landscape with 14 programs across 8 companies. The most active players are Pfizer, Arog Pharmaceuticals, Inc., Gracell Biotechnologies (Shanghai) Co., Ltd.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1G

Gracell Biotechnologies (Shanghai) Co., Ltd.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2E

Essen Biotech

1 program

Phase 2Argenx logo

Argenx

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Small molecule643%
Cell therapy321%
Monoclonal antibody214%
Protein / enzyme214%
Peptide17%

Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

13

clinical trials

Recruiting3 · 23%
Unknown status3 · 23%
Completed2 · 15%
Terminated2 · 15%
Active, not recruiting1 · 8%
Enrolling by invitation1 · 8%
Other1 · 8%

Clinical Trials

Trial Activity

13 trials

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
Recruiting·—·Phase 1·NCT07086404·12 enrolled
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Recruiting·RRestem, LLC.·Phase 2/3·NCT07160205·40 enrolled
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Recruiting·CCabaletta Bio·Preclinical·NCT06154252·74 enrolled
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Active, not recruiting·Argenx logoArgenx·Phase 2/3·NCT05523167·265 enrolled
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)
Not yet recruiting·XXencor, Inc.·Phase 1·NCT07284797·27 enrolled
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Enrolling by invitation·Argenx logoArgenx·Phase 3·NCT05979441·240 enrolled
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT02971683·149 enrolled
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Completed·Octapharma logoOctapharma·Phase 3·NCT02728752·95 enrolled
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
Terminated·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT06462144·3 enrolled
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
Terminated·NNorthwestern University·Phase 1·NCT00278564·7 enrolled
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
Unknown status·IImmunoforge Co. Ltd.·Phase 2·NCT05833711·39 enrolled
Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
Unknown status·PPeking University People's Hospital·Phase 2·NCT04237987·20 enrolled
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
Unknown status·PPeking University People's Hospital·Phase 2·NCT04062019·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)